The current investigation examines gastric adenocarcinomas that have acquired CDX2 mRNA up-regulation for their concomitant expression of SOX2 and compares CDX2 up-regulated cancers that maintained SOX2 expression with CDX2 up-regulated cancers that have acquired concomitant SOX2 suppression. This evidence concerns the gene SOX2 and cancer.